420 related articles for article (PubMed ID: 15101995)
21. Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion.
Liu CJ; Chen PJ; Lai MY; Kao JH; Chen DS
J Med Virol; 2004 Oct; 74(2):237-45. PubMed ID: 15332272
[TBL] [Abstract][Full Text] [Related]
22. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
[TBL] [Abstract][Full Text] [Related]
23. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
[TBL] [Abstract][Full Text] [Related]
24. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations.
Watanabe K; Takahashi T; Takahashi S; Okoshi S; Ichida T; Aoyagi Y
J Gastroenterol Hepatol; 2005 Mar; 20(3):441-9. PubMed ID: 15740490
[TBL] [Abstract][Full Text] [Related]
25. Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy.
Buti M; Jardi R; Rodriguez-Frias F; Valdes A; Schaper M; Esteban R; Guardia J
Aliment Pharmacol Ther; 2005 Jun; 21(11):1349-56. PubMed ID: 15932365
[TBL] [Abstract][Full Text] [Related]
26. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.
Chang UI; Lee YC; Wie SH; Jang JW; Bae SH; Choi JY; Yang JM; Yoon SK; Sun HS
J Med Virol; 2007 Jul; 79(7):902-10. PubMed ID: 17516533
[TBL] [Abstract][Full Text] [Related]
27. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy.
Ciancio A; Smedile A; Rizzetto M; Lagget M; Gerin J; Korba B
Hepatology; 2004 Jan; 39(1):64-73. PubMed ID: 14752824
[TBL] [Abstract][Full Text] [Related]
28. Basal core promoter, precore region mutations of HBV and their association with e antigen, genotype, and severity of liver disease in patients with chronic hepatitis B in India.
Chauhan R; Kazim SN; Bhattacharjee J; Sakhuja P; Sarin SK
J Med Virol; 2006 Aug; 78(8):1047-54. PubMed ID: 16789012
[TBL] [Abstract][Full Text] [Related]
29. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
[TBL] [Abstract][Full Text] [Related]
30. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment.
Yuen MF; Sablon E; Libbrecht E; Van De Velde H; Wong DK; Fung J; Wong BC; Lai CL
Antivir Ther; 2006; 11(6):779-86. PubMed ID: 17310822
[TBL] [Abstract][Full Text] [Related]
31. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.
Tacke F; Gehrke C; Luedde T; Heim A; Manns MP; Trautwein C
J Virol; 2004 Aug; 78(16):8524-35. PubMed ID: 15280461
[TBL] [Abstract][Full Text] [Related]
32. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
33. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis B virus genotypes and precore/core-promoter mutations in Tunisian patients with chronic hepatitis B virus infection.
Ayed K; Gorgi Y; Ayed-Jendoubi S; Aouadi H; Sfar I; Najjar T; Ben Abdallah T
J Infect; 2007 Mar; 54(3):291-7. PubMed ID: 16911832
[TBL] [Abstract][Full Text] [Related]
35. Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B.
Lin CL; Liao LY; Wang CS; Chen PJ; Lai MY; Chen DS; Kao JH
Liver Int; 2005 Jun; 25(3):564-70. PubMed ID: 15910494
[TBL] [Abstract][Full Text] [Related]
36. Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus.
Yuen MF; Sablon E; Yuan HJ; Hui CK; Wong DK; Doutreloigne J; Wong BC; Chan AO; Lai CL
J Infect Dis; 2002 Nov; 186(9):1335-8. PubMed ID: 12402204
[TBL] [Abstract][Full Text] [Related]
37. [Mutations in precore/basal core promoter regions and viral polymerase in patients with chronic hepatitis B].
GutiƩrrez A; Viciana I; Rius F; Pinedo A
Enferm Infecc Microbiol Clin; 2012 Feb; 30(2):70-4. PubMed ID: 22112677
[TBL] [Abstract][Full Text] [Related]
38. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
Zhu Y; Curtis M; Borroto-Esoda K
Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.
Alexopoulou A; Theodorou M; Dourakis SP; Karayiannis P; Sagkana E; Papanikolopoulos K; Archimandritis AJ
J Viral Hepat; 2006 Sep; 13(9):591-6. PubMed ID: 16907845
[TBL] [Abstract][Full Text] [Related]
40. [Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects].
Yuan J; Zhou BP; Gong ZJ; Xu LM; Jiang XL; Mizokami M
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Mar; 20(1):30-2. PubMed ID: 16642214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]